Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Abstract
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment with ruxolitinib resulted in clinical improvements in polycythemia vera and increased survival in primary myelofibrosis.
“Treatment with the JAK1/2 inhibitor ruxolitinib resulted in clinical improvements in polycythemia vera and an increased survival in primary myelofibrosis. 32 , 33”
From Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting (2022) · cites this paper as [32]
Cited by
Sorted by citations
Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting
Zanders, L., Kny, M., Hahn, A., Schmidt, S., Wundersitz, S., Todiras, M., Lahmann, I., Bandyopadhyay, A., Wollersheim, T., Kaderali, L., et al. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12867 · Cited by 225 · see citing works
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
Fisher, D. A. C., Fowles, J. S., Zhou, A., & Oh, S. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683401 · Cited by 115 · see citing works
- Authors
- Vannucchi, A. M.
- Corresponding author
- Alessandro Maria Vannucchi
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-23
- Volume
- 372
- Issue
- 17
- Pages
- 1670-1671
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4242351610
- Cited by
- 108
- References
- 0
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 3 · 2023: 13 · 2022: 3 · 2021: 13 · 2020: 8 · 2019: 12 · 2018: 21 · 2017: 11 · 2016: 9 · 2015: 9
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- ruxolitinib, polycythemia vera, JAK inhibitors, standard treatment, myeloproliferative neoplasms, treatment comparison
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
